1. Everage N et al. Safety and effectiveness of delayed-release dimethyl fumarate in multiple sclerosis patients treated in routine medical practice: the first interim analysis of ESTEEM. ECTRIMS 2016; Poster EP1485.
2. Fachinformation Vumerity®, Stand November 2021.
3. Gold R, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study. Mult Scler 2017;23:253–65.
4. Gold R, et al. Overall safety and efficacy through 10 years of treatment with delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis. ACTRIMS/ECTRIMS 2020;Abstract FC02.05
5. Gold R, et al. Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: Final ENDORSE study results. Mult Scler 2021;(Sep 1):13524585211037909
6. Hemmer B, et al. S2k-Leitlinie, 2021. In: Deutsche Gesellschaft für Neurologie (Hrsg.) Online: www.dgn.org/leitlinien (Zugriff am 13.12.201).
7. Naismith RT, et al. Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: Interim safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler J 2020;26:1729–39.
8. Naismith RT, et al. Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: Results from the randomized, double-blind, phase III EVOLVE-MS-2 study. CNS Drugs 2020;34:1885–99.
9. Palte MJ, et al. Improving the gastrointestinal tolerability of fumaric aAcid esters: Early findings on gastrointestinal events with diroximel fumarate in patients with relapsing-remitting multiple sclerosis from the phase 3, open-label EVOLVE-MS-1 study. Adv Ther 2019;36:3154–65.
10. Sammarco C, et al. Strategies to reduce adverse events related to oral dimethyl fumarate. ECTRIMS 2014; Poster P311.
11. Wehr A, et al. Relative bioavailability of monomethyl fumarate after administration of ALKS 8700 and dimethyl fumarate in healthy subjects. AAN 2018; Poster P403.
12. Wundes A, et al. Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study. Ther Adv Neurol Disord 2021;14:1756286421993999.